1. CSF/serum matrix metallopeptidase-9 ratio discriminates neuro Behçet from multiple sclerosis
- Author
-
Alessandro Barilaro, Mario Milco D'Elios, Alessandra Aldinucci, Giacomo Emmi, Tiziana Biagioli, Anna Maria Repice, Clara Ballerini, Elena Silvestri, Elena Bonechi, and Lorenzo Emmi
- Subjects
030203 arthritis & rheumatology ,business.industry ,General Neuroscience ,Multiple sclerosis ,MMP9 ,Brief Communication ,medicine.disease ,eye diseases ,body regions ,stomatognathic diseases ,03 medical and health sciences ,Interleukin 10 ,0302 clinical medicine ,Cerebrospinal fluid ,Immunology ,medicine ,Interleukin 23 ,CXCL10 ,Neurology (clinical) ,Interleukin 8 ,CXCL13 ,Brief Communications ,business ,030217 neurology & neurosurgery - Abstract
In neuro Behçet disease with multiple sclerosis‐like features, diagnosis could be challenging. Here, we studied the cerebrospinal fluid and serum inflammatory profile of 11 neuro Behçet and 21 relapsing‐remitting multiple sclerosis patients. Between the soluble factors analyzed (MMP9, TNF α, IL6, CXCL13, CXCL10, CXCL8, IFN γ, IL10, IL17, IL23, and others) we found MMP9 increased in neuro Behçet serum compared to multiple sclerosis and decreased in cerebrospinal fluid. Furthermore, neuro Behçet analysis of circulating natural killer CD56DIM subset suggests their potential involvement in increased MMP9 production. We believe that these findings may have a translational utility in clinical practice.
- Published
- 2018